New York, Jan 12, 2026, 05:29 EST — Premarket
Tempus AI, Inc. shares were up about 11% in premarket trading on Monday after the company flagged strong preliminary 2025 results and reported record contract value with drugmakers. Tempus AI traded at $73.66 in premarket action, after ending Friday at $66.27.
The update lands as investors head into the annual J.P. Morgan Healthcare Conference week, when companies often try to reset expectations and pitch their 2026 story. Tempus has been a high-beta name in that mix, moving sharply on growth signals.
For Tempus, the market focus has narrowed to two levers: test volumes in its Diagnostics business and the pace of data licensing in its Data and applications segment. Monday’s disclosures speak to both, and that is why the stock is in motion before the bell.
Tempus said full-year 2025 revenue was about $1.27 billion, up roughly 83% year-on-year, including about 30% organic growth — meaning excluding acquired revenue — and it put Diagnostics revenue at about $955 million. It also said Data and applications revenue was about $316 million, with fourth-quarter revenue around $367 million; founder and CEO Eric Lefkofsky called 2025 “an exceptional year” in a statement. Tempus
Separately, Tempus said total contract value — the headline value of signed deals — exceeded $1.1 billion as of Dec. 31, 2025, and it reported 2025 net revenue retention of about 126%. The company said it signed data agreements with more than 70 customers in 2025, including AstraZeneca, Pfizer, Merck, Novartis and other large drugmakers; CFO Jim Rogers said engagement with life sciences customers “has never been stronger.” Business Wire
Contract value can be a noisy metric: it often spans multiple years, and revenue shows up later as work is delivered. Net revenue retention, meanwhile, tracks whether existing customers spend more over time after accounting for churn — traders watch it as a read on expansion demand.
Tempus sits in a crowded corner of precision medicine where diagnostics players and data vendors all chase the same pharma budgets. Investors often stack its growth rates against oncology testing peers such as Guardant Health and Natera, even when product lines differ.
What comes next is the part that usually moves the stock more than the headline percentages: details. Traders will listen for color on 2026 demand, how quickly contract value converts into recognized revenue, and whether growth is broad-based or concentrated in a few large partners.
But Tempus also stressed a caveat investors have learned not to ignore: the figures are preliminary and unaudited, and the company said final results could differ, potentially materially, as it finishes its year-end close. A gap there — or softer-than-expected guidance later — is the simple downside case for a stock already prone to sharp swings.
The next near-term catalyst is Lefkofsky’s scheduled appearance at the J.P. Morgan Healthcare Conference on Monday, with a presentation and Q&A set for 1:30 p.m. to 2:10 p.m. PST. The company has also said it plans to provide complete fourth-quarter and full-year results on an earnings call in February.
